Interim report July - September 2019.

The full Interim report is available on Brighter's website https://brighter.se. The Interim report is also attached as a pdf file to this press release.

July - September 2019.

• Capitalized expenditure for development work reached SEK 6,273 thousand (2,404).  
• Operating result amounted to SEK -12,637 thousand (-12,017).
• Result before tax amounted to SEK -15,686 thousand (-12,975).
• Earnings per share, before dilution amounted to SEK -0.17 (-0.15).

January - September 2019.

• Capitalized expenditure for development work reached SEK 24,834 thousand (13,945).
• Operating result amounted to SEK -44,781 thousand (-37,761)
• Result before tax amounted to SEK -55,158 thousand (-39,939).
• Earnings per share, before dilution amounted to SEK -0.68 (-0.57).

Financial overview.

For definitions, see note 26 in Brighter’s 2018 Annual Report.

Significant events during the period.

• Brighter carried out a directed share issue of SEK 10.8 million through set-off and cash.
• Brighter carried out a directed share issue of SEK 5 million.
• All L1 Capital convertibles have now been converted and the agreement with L1 Capital is thus fulfilled.
• Actiste – world’s first unified IoT diabetes care device – received market approval (CE mark).
• Brighter carried out a directed share issue of SEK 35.4 million.
• Petra Kaur, formerly Chief Communications and Marketing Officer, has assumed the role of Chief Commercial and Marketing Officer. 
• Brighter's main patent was granted in Brazil.
• The number of shares in Brighter AB has increased. The total number of shares and votes increased from 83,823,170 to 85,720,621.

Significant events after the end of the period.

• Brighter officially kicked-off commercial phase at GITEX in Dubai.
• Brighter acquired 100% of Camanio Care AB (publ)'s subsidiary Camanio AB and sold its holding in Camanio Care AB (publ).
• The number of shares in Brighter AB has increased. The total number of shares and votes increased from 85,720,621 to 93,397,483.

CEO statement.
The great news from Q3 was the Actiste device receiving the EC certifications (CE-marks) we have worked so hard towards. We can now move forward with the other activities related to commercialising Actiste Diabetes Management as a Service. This crucial development substantially reduces Brighter's risk profile. 

We enter our commercialisation phase with an improved balance sheet, thanks to the directed share issue of SEK 35.4 million we carried out in early September. Brighter’s balance sheet is now completely cleared of interest-bearing loans.

In Q3, we signed a letter of intent to acquire all the shares in a subsidiary of Camanio Care AB (publ). We completed the acquisition in mid-October, creating the new standalone subsidiary Camanio AB. In connection to the acquisition, Brighter also sold all its shares in Camanio Care AB (publ). From a financial accounting perspective, Camanio AB will be integrated into the Brighter Group, and all our ties to Camanio Care AB (publ) will cease to exist. As part of the transaction, Camanio Care AB (publ) has changed its objective and will change its name, in order not to be confused with Camanio AB.

Our team in the United Arab Emirates – led by Kristian Sandberg – continues to work on commercializing Actiste Diabetes Management as a Service. Now that the Actiste device has received EC certifications, we are moving ahead with the local registration procedures. As a precursor to this, we officially launched Actiste Diabetes Management as a Service at the GITEX Technology Week in Dubai in early October. 

Our regional strategy for launching Actiste remains as previously communicated: first the UAE and Sweden, and then Gulf Cooperation Council countries and Southeast Asia. Our original patent, used for developing Actiste, has now also been granted in Brazil. Although local approval of patents is not a prerequisite for entering a specific market, it increases the overall value of Brighter's IP portfolio.

We look forward to an exciting period ahead.

Best wishes,
Henrik Norström, CEO of Brighter AB.

For further information, please contact:

Henrik Norström, CEO
Phone: +46 73 340 30 45
E-mail: Henrik.norstrom@brighter.se

Ann Zetterberg, CFO
Phone: +46 70 837 21 23
E-mail: ann.zetterberg@brighter.se

About Brighter AB (publ).
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se.

This information is such information, as Brighter AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact persons for publication on October 25^th, 2019 at 08:00 CET.